PDF(Pubmed)
Abstract：
UNASSIGNED: Hepatitis delta virus (HDV) infection has been granted orphan disease status by the US Food and Drug Administration and the European Medicines Agency owing to its rarity and relatively limited research and treatment options. Turkey is considered an endemic country for the virus. We aimed to provide a current and updated country- and region-specific HDV infection prevalence.
UNASSIGNED: In this meta-analysis, we searched databases, including MEDLINE, PUBMED, EMBASE, and UlakBim (Turkish Medical Index) published between January 1, 2006, and December 31, 2022. We included blood donor studies, outpatient clinic studies that comprised patients without cirrhosis, and inpatient clinical studies that comprised patients with cirrhosis. Turkey was divided into three regions: West, Central, and East Turkey.
UNASSIGNED: After a systematic assessment, 41 studies were included. Using a random-effects model, the estimated HDV prevalence among hepatitis B surface antigen-positive blood donors, outpatient clinic, and inpatient clinic patients were 3.37% (confidence interval [CI] 1.99-6.11), 5.05% (CI 4.00-6.23), and 29.06% (CI 10.45-51.79), respectively. The HDV prevalence among outpatient clinic patients in Western, Central, and Eastern regions were 3.38% (CI 2.47-4.44), 2.15% (CI 1.37-3.09), and 9.81% (CI 6.61-13.55), respectively.
UNASSIGNED: East Turkey continues to have a high burden of HDV. Public health efforts, such as screening, should be targeted accordingly.
UNASSIGNED: In this meta-analysis, we searched databases, including MEDLINE, PUBMED, EMBASE, and UlakBim (Turkish Medical Index) published between January 1, 2006, and December 31, 2022. We included blood donor studies, outpatient clinic studies that comprised patients without cirrhosis, and inpatient clinical studies that comprised patients with cirrhosis. Turkey was divided into three regions: West, Central, and East Turkey.
UNASSIGNED: After a systematic assessment, 41 studies were included. Using a random-effects model, the estimated HDV prevalence among hepatitis B surface antigen-positive blood donors, outpatient clinic, and inpatient clinic patients were 3.37% (confidence interval [CI] 1.99-6.11), 5.05% (CI 4.00-6.23), and 29.06% (CI 10.45-51.79), respectively. The HDV prevalence among outpatient clinic patients in Western, Central, and Eastern regions were 3.38% (CI 2.47-4.44), 2.15% (CI 1.37-3.09), and 9.81% (CI 6.61-13.55), respectively.
UNASSIGNED: East Turkey continues to have a high burden of HDV. Public health efforts, such as screening, should be targeted accordingly.
摘要：
■丁型肝炎病毒（HDV）感染已被美国食品和药物管理局和欧洲药品管理局授予孤儿病状态，由于其罕见且研究和治疗选择相对有限。土耳其被认为是该病毒的流行国家。我们旨在提供当前和最新的国家和地区特定的HDV感染率。
■在此荟萃分析中，我们搜索了数据库,包括MEDLINE,pubmed,EMBASE,和UlakBim（土耳其医学索引）在2006年1月1日至2022年12月31日之间发布。我们纳入了献血者的研究,包括没有肝硬化的患者的门诊临床研究，以及包括肝硬化患者的住院临床研究。土耳其分为三个地区：西部，中央,土耳其东部。
■经过系统评估，纳入41项研究。使用随机效应模型，估计乙型肝炎表面抗原阳性献血者的HDV患病率，门诊,住院门诊患者为3.37%(置信区间[CI]1.99-6.11)，5.05%（CI4.00-6.23），和29.06%（CI10.45-51.79），分别。西医门诊患者的HDV患病率，中央,东部地区为3.38%(CI2.47-4.44)，2.15%（CI1.37-3.09），和9.81%（CI6.61-13.55），分别。
■东土耳其仍然有很高的HDV负担。公共卫生工作，比如筛查，应该有针对性。
■在此荟萃分析中，我们搜索了数据库,包括MEDLINE,pubmed,EMBASE,和UlakBim（土耳其医学索引）在2006年1月1日至2022年12月31日之间发布。我们纳入了献血者的研究,包括没有肝硬化的患者的门诊临床研究，以及包括肝硬化患者的住院临床研究。土耳其分为三个地区：西部，中央,土耳其东部。
■经过系统评估，纳入41项研究。使用随机效应模型，估计乙型肝炎表面抗原阳性献血者的HDV患病率，门诊,住院门诊患者为3.37%(置信区间[CI]1.99-6.11)，5.05%（CI4.00-6.23），和29.06%（CI10.45-51.79），分别。西医门诊患者的HDV患病率，中央,东部地区为3.38%(CI2.47-4.44)，2.15%（CI1.37-3.09），和9.81%（CI6.61-13.55），分别。
■东土耳其仍然有很高的HDV负担。公共卫生工作，比如筛查，应该有针对性。
